Dysmenorrhea Treatment Market size, share, forecast 2022

1
Dysmenorrhea Treatment Market -
Overview Dysmenorrhea refers to the painful
menstruation women experience during their
monthly discharging periods. While it is normal
for women to have mild abdominal cramps on the
initial days of their menstruation, about 30 of
women experience severe pain along with headaches
and nausea that could be termed as Dysmenorrhea.
Over the past decade, the prevalence of
Dysmenorrhea is observed to be growing. Reasons
could be environmental changes, change in diet,
and lack of nutritious diet, etc. However, the
cause acting as the driving force to prevail
these conditions is changing and unhealthy
lifestyle. Todays working women have to cope-up
with physical as well as mental stress
encountered at both the fronts personal
(family) and workplace. Growing awareness among
women towards the fact that Dysmenorrhea can now
be treated and the availability and accessibility
of treatments are encouraging the increasing
number of women to avail the advantages of these
treatments. Resultantly, Dysmenorrhea market is
growing pervasively, becoming a lucrative
space. Acknowledging the exponential growth the
market perceives currently Market Research
Future (MRFR), in its recently published market
forecast asserts that the global Dysmenorrhea
Treatment Market will reach USD 8.40 Bn. by 2023,
registering a striking CAGR of 12.28 throughout
the forecast period (2017 2023). In 2016, the
market had valued at USD 5.68 Bn. List of Key
Companies Covered in this report Johnson
Johnson (US), GlaxoSmithKline PLC (UK),
Hoffmann-La Roche Ltd (Switzerland), Bayer AG
(Germany), Focus Consumer Healthcare, LLC (US),
Novartis AG (Switzerland), Pfizer, Inc. (US),
Reckitt Benckiser Group plc. (UK), Sanofi S.A.
(France), Viatris Inc. (US) Dysmenorrhea
Treatment Market - Segmentations MRFR has
segmented the report into three key dynamics for
an easy grasp and enhanced understanding- By
Type Primary and Secondary (Adenomyosis,
Endometriosis, Uterine myomas, Cervical stenosis,
Endometrial polyps, and Obstructive malformations
of genital tract.). By Treatment Non-Steroidal
Anti-Inflammatory Drugs (Nsaids), Hormonal, and
Combined Oral Contraceptive among others. By
End-User Hospitals, Clinics, Diagnostic
Centers, and Pharmaceutical Companies among
Others. By Regions North America, Europe, APAC
and Rest of the World. Global Dysmenorrhea
Treatment Market - Competitive Landscape The
competitive market for Dysmenorrhea Treatment is
fragmented with many large and small players
operating in the market. Market players
incorporate acquisition, collaboration,
expansion, technology launch and strategic
partnership. These players substantially invest
in RD and clinical trials to develop effective
drugs. To help accelerate pharmaceutical
innovations and to gain a better understanding of
the conditions, these pharma companies
collaborate with academia and the biotech
industry partners who can contribute cutting-edge
technologies and specialized knowledge. These
collaborations are one of the innovation
strategies of market players. Companies can
leverage the latest scientific knowledge
2
and translate it into innovative medicines
through partnering. These partnerships can kindle
the innovative impulses that advance medicine and
benefit patients as well as partners. Global
Dysmenorrhea Treatment Market - Regional
Analysis Globally North America leads the
Dysmenorrhea Treatment market with the
significant market share. The Market is expected
to grow phenomenally from 2017 to 2023.
Attributing to the favorable reimbursement
scenario and higher expenditure on healthcare the
market is expected to perceive a healthy
growth. The factor contributing to the market
growth include increasing prevalence of issues
and disorders associated with womens
reproductive system fuelled by the changing
lifestyle and growing awareness towards the
availability of the treatments. The US, backed by
the technological advances and availability of
funding for the development of new therapeutics
and treatment accounts for the major contributor
to the market growth. Europe emerging as a
lucrative market for Dysmenorrhea Treatment will
expand registering a phenomenal CAGR. The
resurging economy in the region is expected to
foster the regional market growth, increasing per
capita healthcare expenditures. The financial
support provided by private and governments
bodies for RD activities and new improved
reimbursement policies in healthcare will fuel
the Dysmenorrhea Treatment market in
Europe. Industry/Innovation/ Related
News January 04, 2018 Pfizer Inc. (US) a
pharmaceutical conglomerate announced the
partnership with 23andMe (US), a privately held
personal genomics and biotechnology company to
aid understanding of depression, dysmenorrhea and
the genetic heterogeneity of lupus and
inflammatory bowel disease. Pfizer believes that
such collaborations will help it to potentially
usher in a new era of patient care defined by
targeted research methods and ultimately better
patient outcomes. About US Market Research
Future (MRFR) enable customers to unravel the
complexity of various industries through Cooked
Research Report (CRR), Half-Cooked Research
Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market
Research Consulting Services. Contact
us Market Research Future (part of Wantstats
Research and Media Private Limited), 99 Hudson
Street,5Th Floor, New York, New York 10013